Stock Analysis
- United Kingdom
- /
- Life Sciences
- /
- AIM:FAB
Fusion Antibodies Full Year 2023 Earnings: UK£0.10 loss per share (vs UK£0.046 loss in FY 2022)
Fusion Antibodies (LON:FAB) Full Year 2023 Results
Key Financial Results
- Revenue: UK£2.90m (down 40% from FY 2022).
- Net loss: UK£2.60m (loss widened by 116% from FY 2022).
- UK£0.10 loss per share (further deteriorated from UK£0.046 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Fusion Antibodies shares are down 12% from a week ago.
Risk Analysis
Be aware that Fusion Antibodies is showing 7 warning signs in our investment analysis and 5 of those are concerning...
Valuation is complex, but we're helping make it simple.
Find out whether Fusion Antibodies is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:FAB
Fusion Antibodies
A contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.
Medium-low with adequate balance sheet.